Patent · US Active

T cell receptors with mage-B2 specificity and uses thereof

US12202877B2 · kind B2 · utility

0Cited by
0References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 19, 2019
Grant dateJan 21, 2025
Priority date—
Expiry dateJan 22, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.